Vol 9, No 6 (December 2020): Translational Lung Cancer Research

Original Article

Pre-radiotherapy lymphocyte count and platelet-to-lymphocyte ratio may improve survival prediction beyond clinical factors in limited stage small cell lung cancer: model development and validation
Yishan Yu, Linlin Wang, Shufen Cao, Siming Gao, Weili Wang, Lianne Mulvihill, Mitchell Machtay, Pingfu Fu, Jinming Yu, Feng-Ming (Spring) Kong
Stereotactic body radiotherapy for early stage non-small cell lung cancer in patients with subclinical interstitial lung disease
Yuanjun Liu, Yaoyao Zhu, Ran Wu, Min Hu, Lingnan Zhang, Qingren Lin, Denghu Weng, Xiaojiang Sun, Yu Liu, Yaping Xu
Metformin reverses chemoresistance in non-small cell lung cancer via accelerating ubiquitination-mediated degradation of Nrf2
Sha Huang, Tianyu He, Sijia Yang, Hongxu Sheng, Xiuwen Tang, Feichao Bao, Yiqing Wang, Xu Lin, Wenfeng Yu, Fei Cheng, Wang Lv, Jian Hu
Investigation on the potential of circulating tumor DNA methylation patterns as prognostic biomarkers for lung squamous cell carcinoma
Yutao Liu, Yu Feng, Ting Hou, Analyn Lizaso, Feng Xu, Puyuan Xing, Hongyu Wang, Qiaolin Kang, Lu Zhang, Yuankai Shi, Xingsheng Hu
Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy
Yanjun Xu, Hui Li, Zhiyu Huang, Kaiyan Chen, Xiaoqing Yu, Jiamin Sheng, Han-Han Zhang, Yun Fan
The feasibility of navigation bronchoscopy-guided pulmonary microcoil localization of small pulmonary nodules prior to thoracoscopic surgery
Junxiang Chen, Xufeng Pan, Chuanjia Gu, Xiaoxuan Zheng, Haibin Yuan, Jun Yang, Jiayuan Sun
Immunotherapy beyond progression in patients with advanced non-small cell lung cancer
Xiangwei Ge, Zhibo Zhang, Sujie Zhang, Fang Yuan, Fan Zhang, Xiang Yan, Xiao Han, Junxun Ma, Lijie Wang, Haitao Tao, Xiaoyan Li, Xiaoyu Zhi, Zhiyue Huang, Paul Hofman, Arsela Prelaj, Giuseppe Luigi Banna, Luciano Mutti, Yi Hu, Jinliang Wang
Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study
Ziqing Zeng, Bo Yan, Yulong Chen, Lianmin Zhang, Jianquan Zhu, Fan Yang, Feng Wei, Terence Chi Chun Tam, Diego Kauffmann-Guerrero, Ross Andrew Soo, Xiubao Ren, Jian You
Hsa_circ_0006571 promotes spinal metastasis through sponging microRNA-138 to regulate sirtuin 1 expression in lung adenocarcinoma
Hou-Lei Wang, Hui-Ren Wang, Yun Liang, An-Nan Hu, Francisco J. Enguita, Xiao-Gang Zhou, Jian Dong
Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD)
Tongji Xie, Yan Li, Jianming Ying, Weijing Cai, Junling Li, Kye Young Lee, Biagio Ricciuti, Jose Pacheco, Puyuan Xing
The protective effects of granulocyte-macrophage colony-stimulating factor against radiation-induced lung injury
Dan Hu, Yan Zhang, Ruiqi Cao, Yuying Hao, Xiaoye Yang, Tiantian Tian, Jiandong Zhang

Editorial on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions1

Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going?
Francesco Passiglia, Silvia Novello

Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions1

How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)
Bing Xia, Misako Nagasaka, Viola W. Zhu, Sai-Hong Ignatius Ou, Ross A. Soo
How selecting best therapy for metastatic NTRK fusion-positive non-small cell lung cancer?
Simon Ekman
Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won
Fabrizio Tabbò, Maria Lucia Reale, Paolo Bironzo, Giorgio V. Scagliotti
The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
Ibiayi Dagogo-Jack, Lauren L. Ritterhouse
Decade in review: a new era for RET-rearranged lung cancers
Noura J. Choudhury, Alexander Drilon
Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies
Alessandro Russo, Andrés F. Cardona, Christian Caglevic, Paolo Manca, Alejandro Ruiz-Patiño, Oscar Arrieta, Christian Rolfo
Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?
Janna Josephus Anna Oda Schoenmaekers, Marthe Sentijna Paats, Anne-Marie Clasina Dingemans, Lizza Elisabeth Lucia Hendriks
Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
Kenichi Suda, Tetsuya Mitsudomi
Future perspectives from lung cancer pre-clinical models: new treatments are coming?
Francesca Bersani, Deborah Morena, Francesca Picca, Alessandro Morotti, Fabrizio Tabbò, Paolo Bironzo, Luisella Righi, Riccardo Taulli
Narrative review of molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung carcinomas
Matthias S. Matter, Obinna Chijioke, Spasenija Savic, Lukas Bubendorf
Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review
Ana Ortega-Franco, Virginia Calvo, Fabio Franco, Mariano Provencio, Raffaele Califano
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review
Gianmarco Leone, Francesco Passiglia, Paolo Bironzo, Valentina Bertaglia, Silvia Novello
How selecting best upfront therapy for metastatic disease?—Focus on ROS1-rearranged disease
Lorenza Landi, Federico Cappuzzo

Consensus

Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer
Wenhua Liang, Kaican Cai, Chun Chen, Haiquan Chen, Qixun Chen, Junke Fu, Jian Hu, Tao Jiang, Wenjie Jiao, Shuben Li, Changhong Liu, Deruo Liu, Wei Liu, Yang Liu, Haitao Ma, Xiaojie Pan, Guibin Qiao, Hui Tian, Li Wei, Yi Zhang, Song Zhao, Xiaojing Zhao, Chengzhi Zhou, Yuming Zhu, Ran Zhong, Feng Li, Rafael Rosell, Mariano Provencio, Erminia Massarelli, Mara B. Antonoff, Toyoaki Hida, Marc de Perrot, Steven H. Lin, Massimo Di Maio, Antonio Rossi, Dirk De Ruysscher, Robert A. Ramirez, Wolfram C. M. Dempke, D. Ross Camidge, Nicolas Guibert, Raffaele Califano, Qi Wang, Shengxiang Ren, Caicun Zhou, Jianxing He

Disclosure:

1. The series “Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Silvia Novello and Francesco Passiglia served as the unpaid Guest Editors for the series.